Pfizer (PFE) Ticks Higher; Prevenar 13 Met Primary Objective
Tweet
Share
E-mailGet Alerts PFE Hot Sheet
Price: $25.01 +0.40%
Overall Analyst Rating:
SELL (= Flat)
Dividend Yield: 6.9%
EPS Growth %: -12.8%
Overall Analyst Rating:
SELL (= Flat)
Dividend Yield: 6.9%
EPS Growth %: -12.8%
Join SI Premium – FREE
Pfizer (NYSE: PFE) shares are ticking higher following new top-line data from its Prevenar 13 (Pneumococcal polysaccharide conjugate vaccine [13-valent, absorbed]) in adults 18 to 49 years of age.
Data shows Prevenar 13 met the primary objective for all 13 stereotypes and Pfizer will support further regulatory submissions.
Shares are up about 0.2 percent ahead of the bell.
Data shows Prevenar 13 met the primary objective for all 13 stereotypes and Pfizer will support further regulatory submissions.
Shares are up about 0.2 percent ahead of the bell.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- U.S. biopharma earnings: Eli Lilly (LLY), Pfizer (PFE) take the stage
- FDA advisory panel votes 10-3 in favor of Replimune's melanoma drug
- Aprea expands cancer trial sites and plans Q4 2026 data update
Create E-mail Alert Related Categories
FDA, Insiders' BlogSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
